However, no clinical trials have assessed the effectiveness of fingolimod in cancer, potentially due to the impairment of cytotoxic CD8+ T and CD4+ T cell trafficking and activation, which precludes tumor infiltration to kill cancer cells. This evidence concerns the gene CD8A and neoplasm.